Physician profile
James Broadbent
NPI 1619544293
$494.36
in general payments reported to CMS, 2019-2025
12 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.04 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $120.76 | 2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $98.09 | 2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $54.63 | 2025 | |
| Cleerly, INC. | $47.86 | 2025 | Cleerly Labs |
| Phathom Pharmaceuticals, INC. | $31.65 | 2025 | Voquezna |
| Lucid Diagnostics INC. | $29.07 | 2025 | |
| Gilead Sciences, INC. | $23.85 | 2025 | |
| Amgen INC. | $20.61 | 2025 | Repatha, Otezla |
| Azurity Pharmaceuticals, INC. | $18.16 | 2025 | Edarbi |
| Organon LLC | $17.04 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.43 | 2025 | Airsupra |
| Astellas Pharma US INC | $16.21 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Broadbent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.